CDG Stock Overview
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Acorda Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.42 |
| 52 Week High | US$21.80 |
| 52 Week Low | US$5.64 |
| Beta | 1.43 |
| 1 Month Change | 0% |
| 3 Month Change | -6.83% |
| 1 Year Change | 10.25% |
| 3 Year Change | -83.90% |
| 5 Year Change | -99.70% |
| Change since IPO | -98.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| CDG | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.9% | -1.5% |
| 1Y | 10.2% | -19.9% | 0.9% |
Return vs Industry: CDG exceeded the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: CDG exceeded the German Market which returned 5.9% over the past year.
Price Volatility
| CDG volatility | |
|---|---|
| CDG Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CDG's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine CDG's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 111 | Ron Cohen | www.acorda.com |
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson’s disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas.
Acorda Therapeutics, Inc. Fundamentals Summary
| CDG fundamental statistics | |
|---|---|
| Market cap | €14.12m |
| Earnings (TTM) | -€19.42m |
| Revenue (TTM) | €108.53m |
0.1x
P/S Ratio-0.7x
P/E RatioIs CDG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDG income statement (TTM) | |
|---|---|
| Revenue | US$116.91m |
| Cost of Revenue | US$27.38m |
| Gross Profit | US$89.53m |
| Other Expenses | US$110.45m |
| Earnings | -US$20.92m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -16.84 |
| Gross Margin | 76.58% |
| Net Profit Margin | -17.89% |
| Debt/Equity Ratio | 259.6% |
How did CDG perform over the long term?
See historical performance and comparison